Search Pay Bill Contact Us Company Innovation Publications Investors Prepare for life. View More Progenity Appoints Adi Mohanty as Chief Executive Officer Learn More Progenity Announces Several Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Ingestible Therapeutics Technologies Learn More Transforming healthcare to be more precise and personal. Progenity is a biotech company with a multi-omics approach. We are combining genomics, epigenomics, proteomics, and metabolomics to improve the diagnosis and treatment of disease. About Us Latest News Progenity Strengthens its Liquidity Position November 23, 2021 Progenity to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference November 15, 2021 View All News Featured Publications Development of a novel drug delivery system to deliver drugs directly... The DDS2 system could result in improved efficacy and reduced systemic exposure for the treatment of ulcerative colitis. Aug 30, 2021 Targeted delivery of tofacitinib citrate to the site of disease to improve... When delivered to the site of inflammation, liquid drug formulations could result in higher tissue absorption and lower drug exposure. May 20, 2021 View All Publications Search the Site Connect With Us Company About Progenity Careers at Progenity Compliance Leadership Privacy & Terms of Use Innovation Preecludia™ Gastrointestinal Health Oral Biotherapeutics Publications Gastrointestinal Health Preeclampsia Investors News & Events Stock Information Corporate Governance Financials & Filings IR Resources © Progenity, Inc. All rights reserved. Progenity® is a registered service mark of Progenity, Inc. Preecludia™ is a trademark of Progenity, Inc. All other trademarks are the property of their respective owners. Please review our updated Website Privacy Policy, which describes our practices related to the collection, use, and disclosure of your personal information.Cookie Policy Cookies Settings Accept All Cookies